Key result
HPV vaccination linked to ~10% lower risk of new-onset cardiovascular disease in young adults.
Why the study?
While human papillomavirus (HPV) is extensively studied for its oncogenic properties, the influence of HPV and the potential protective impact of HPV vaccination on the incidence of cardiovascular and cerebrovascular diseases remained under investigation.
Does human papillomavirus (HPV) vaccination reduce the incidence of new-onset cardiovascular diseases, cerebrovascular diseases, and heart dysfunction in adults aged 20 to 40 years?
Cohort (n=118,846)
Yes
Does human papillomavirus (HPV) vaccination reduce the incidence of new-onset cardiovascular diseases, cerebrovascular diseases, and heart dysfunction in adults aged 20 to 40 years?
Hazard Ratio: 0.9 (95% CI 0.847–0.957)
Absolute Event Rate: 3.26% vs 3.65%
p-value: p=<0.001
In a large US propensity-matched cohort of young adults aged 20–40, HPV vaccination was significantly associated with a lower 3-year risk of new-onset cardiovascular disease, cerebrovascular disease, and heart dysfunction.
Observed CVD risk reduction after HPV vaccination in young adults should not change practice; leaves open causality pending randomized trials.
INTRODUCTION: Human papillomavirus (HPV), a widespread sexually transmitted infection, is well-known for its association with cancers like cervical, anal, and oropharyngeal. While extensively studied for its oncogenic properties, HPV's influence on these non-cancerous conditions remains under investigation. This study examines the impact of HPV vaccination on the incidence of cardiovascular and cerebrovascular diseases, exploring its protective potential. METHODS: Utilizing the global TriNetX database, this retrospective cohort study analyzed data from adults aged 20 to 40 who were either vaccinated or not vaccinated against HPV between January 1, 2019, and December 31, 2021. The study employed propensity score matching to ensure balanced comparison groups and utilized ICD-10 codes to identify new-onset cardiovascular and cerebrovascular diseases. RESULTS: The study included 59,423 vaccinated and an equal number of unvaccinated individuals, balanced for various demographic and health characteristics. The vaccinated group demonstrated a lower incidence of cardiovascular diseases (hazard ratio [HR] = 0.9, 95% CI 0.847-0.957), cerebrovascular diseases (HR = 0.605, 95% CI 0.484-0.754), and heart dysfunction (HR = 0.833, 95% CI 0.708-0.98) compared to the unvaccinated group. Subgroup analyses further supported the protective effect of HPV vaccination across different demographics. CONCLUSION: HPV vaccination is linked to a lower risk of new-onset cardiovascular and cerebrovascular diseases in adults, suggesting broader health benefits beyond cancer prevention. These results advocate for incorporating cardiovascular health into public health strategies promoting HPV vaccination. Further research is necessary to understand the mechanisms and validate these protective effects across diverse populations and extended follow-up periods.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2025) conducted a cohort in New-onset cardiovascular and cerebrovascular diseases (n=118,846). HPV vaccination vs. No HPV vaccination was evaluated on New-onset cardiovascular diseases (ischemic heart diseases and heart failure) (HR 0.9, 95% CI 0.847-0.957, p=<0.001). HPV vaccination was associated with a reduced risk of new-onset cardiovascular diseases (HR 0.9, 95% CI 0.847-0.957) and cerebrovascular diseases (HR 0.605) in adults aged 20-40.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: